masthead-publications

2021

Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure

Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure

Download pdf 3.4MB

CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study.

Pascual, J., et al. CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study. J Clin Oncol 39, 2021 (suppl 15; abstr 1014) DOI: 10.1200/JCO.2021.39.15_suppl.1014

View External Link

Correlate with Improvement in Disease Activity in Patients with Rheumatoid Arthritis on Tumour Necrosis Factor  Inhibitors. Annals of the Rheumatic Diseases

David, T., et al. MiRNAs Correlate with Improvement in Disease Activity in Patients with Rheumatoid Arthritis on Tumour Necrosis Factor  Inihibitors. Annals of the Rheumatic Diseases 2021;80:409; Poster 0357

Download pdf 184KB

Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.

Denkert, C., et al. Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. J Clin Oncol 39, 2021 (suppl 15; abstr 519) DOI: 10.1200/JCO.2021.39.15_suppl.519

View External Link

Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.

Marmé, F., et al. Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. J Clin Oncol 39, 2021 (suppl 15; abstr 518). DOI 10.1200/JCO.2021.39.15_suppl.518

View External Link

MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.

Jose Antonio Lopez Guerrero, et al. MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology. J Clin Oncol 39, 2021 (suppl 15; abstr 558) DOI 10.1200/JCO.2021.39.15_suppl.558

View External Link

2020

Potential Mechanisms of Resistance Identified Through Analysis of Multiple Biomarkers in Immune-Hot Non-Responders with Non-small Cell Lung Cancer Treated with Tislelizumab

Desai, J., et al. Potential Mechanisms of Resistance Identified Through Analysis of Multiple biomarkers in Immune-Hot Non-Responders with Non-small Cell Lung Cancer Treated with Tislelizumab. Poster presented at Society for Immunotherapy of Cancer Virtual Congress. 2020 Nov 9-14

Download pdf 386KB

Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis

Inaki, K., et al. Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis. Abstract presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 June 22-24. Online Proceedings. Session PO.MCB09.01 Functional Genomics and Other Topics

Download pdf 1.1MB
View External Link

Page last updated July 01, 2021